🇺🇸 FDA

Company profile · Sponsor

Summit

Summit Therapeutics

SMMT · NYSE pharma MIAMI, FL, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

Summit (SMMT) is a pharma company. headquartered in MIAMI, FL, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker SMMT
Exchange NYSE
Company type pharma
Headquarters MIAMI, FL, USA
SEC CIK 0001599298

Pipeline (24)

Search pipeline →

  1. AK112 Injection

    Summit

    Non-Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. Acupuncture

    Summit

    Fatigue

    phase 3 other active

    1 trial

  3. Drug: Ivonescimab Injection

    Summit

    Metastatic Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  4. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  5. Ivonescimab 10 mg/kg

    Summit

    Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

    phase 3 small molecule active

    1 trial

  6. Ivonescimab Injection

    Summit

    Non-Small Cell Lung Cancer

    phase 3 mab active

    2 trials

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ivonescimab, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin 10 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion., Pazenir 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Summit

    Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Summit

    Metastatic Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. Ridinilazole

    Summit

    Clostridioides Difficile Infection

    phase 3 small molecule completed

    2 trials

  10. AK112

    Summit

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. Ezutromid

    Summit

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  12. Hyperbaric Oxygen Therapy

    Summit

    TBI Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  13. Ivonescimab

    Summit

    Thymus Carcinoma

    phase 2 mab active

    1 trial

  14. Ivonescimab

    Summit

    Ivonescimab

    phase 2 small molecule active

    1 trial

  15. Ivonescimab

    Summit

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  16. Ivonescimab

    Summit

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. Ivonescimab

    Summit

    Endometrial Cancer

    phase 2 small molecule active

    1 trial

  18. Ivonescimab

    Summit

    Glioblastoma

    phase 2 small molecule active

    1 trial

  19. Ivonescimab

    Summit

    Leiomyosarcoma

    phase 2 small molecule active

    1 trial

  20. Ivonescimab

    Summit

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  21. Ivonescimab

    Summit

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  22. Ivonescimab

    Summit

    Metastatic Esophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. Ivonescimab

    Summit

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    3 trials

  24. Ivonescimab

    Summit

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12318487

    Solid tablet dosage form of ridinilazole

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11344575

    Vascular calcification prevention and treatment

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11007171

    Treatment and prevention of joint disorders

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9763925

    Antibacterial compounds

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9492433

    Pharmaceutical composition for the treatment of Duchenne muscular dystrophy

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9314456

    Antibacterial compounds

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9278091

    Compounds for the treatment of Clostridium difficile associated disease

    Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8987308

    Compounds for the treatment of Clostridium difficile-associated disease

    Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Summit?

Summit (SMMT) is a pharma company. headquartered in MIAMI, FL, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Summit sponsor?

We track 24 ClinicalTrials.gov-linked programs for Summit, including AK112 Injection and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Summit company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.